Evotec (NASDAQ:EVO – Get Free Report) was downgraded by equities researchers at Berenberg Bank from a “buy” rating to a “hold” rating in a report issued on Thursday.
Several other research firms have also commented on EVO. Wall Street Zen lowered shares of Evotec from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings raised shares of Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, April 24th. HC Wainwright reduced their price objective on shares of Evotec from $7.00 to $4.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, TD Cowen lowered Evotec from a “buy” rating to a “hold” rating and set a $2.00 target price for the company. in a report on Wednesday. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Evotec presently has a consensus rating of “Hold” and an average price target of $3.00.
Get Our Latest Stock Analysis on Evotec
Evotec Price Performance
Evotec (NASDAQ:EVO – Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported $0.05 earnings per share for the quarter. The business had revenue of $297.02 million during the quarter. Evotec had a negative return on equity of 24.93% and a negative net margin of 26.20%. As a group, sell-side analysts predict that Evotec will post -0.63 earnings per share for the current year.
Hedge Funds Weigh In On Evotec
Several hedge funds and other institutional investors have recently modified their holdings of EVO. ABC Arbitrage SA lifted its stake in shares of Evotec by 319.7% during the fourth quarter. ABC Arbitrage SA now owns 554,287 shares of the company’s stock worth $1,707,000 after buying an additional 422,230 shares during the period. Wellington Management Group LLP increased its position in shares of Evotec by 25.7% in the 4th quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company’s stock valued at $5,536,000 after acquiring an additional 367,545 shares during the period. Optiver Holding B.V. increased its position in shares of Evotec by 598.4% in the 1st quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock valued at $709,000 after acquiring an additional 242,973 shares during the period. Jane Street Group LLC purchased a new position in Evotec in the 4th quarter worth $565,000. Finally, Millennium Management LLC purchased a new position in Evotec in the 4th quarter worth $317,000. 5.81% of the stock is owned by hedge funds and other institutional investors.
About Evotec
Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.
Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.
Further Reading
- Five stocks we like better than Evotec
- Japan’s Crypto Overhaul Could Open the Door to a Wave of Institutional Money
- Cintas Keeps Beating Expectations—And the Story Isn’t Over
- Which Storage Stock Is Best Positioned to Win the AI Memory War?
- Tesla’s Delivery Surprise Was Big—Earnings Need to Be Bigger
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
